Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
11 hedge funds and large institutions have $1.14M invested in Amplify Treatments, Testing and Advancements ETF in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
12% less capital invested
Capital invested by funds: $1.3M → $1.14M (-$160K)
15% less funds holding
Funds holding: 13 → 11 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$133K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.22K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
+$3.72K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$465 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$203K |
| 2 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$34.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.07K |
| 4 |
Morgan Stanley
New York
|
-$44 |
GERM Hedge Fund Activity: Q1 2024 in Review
11 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q1 2024, worth a combined $1.14M — down 12% from $1.3M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GERM and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $133K. The largest seller was Goldman Sachs, exiting entirely with an estimated $203K sold.
- 11 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q1 2024, down from 13 in Q4 2023.
- Funds reported $1.14M of Amplify Treatments, Testing and Advancements ETF stock for Q1 2024, down 12% quarter-over-quarter.
- 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q1 2024 and 3 closed out, a net change of -2 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q1 2024 was Susquehanna International Group, an estimated $133K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q1 2024 was Goldman Sachs, an estimated $203K sold.
Based on aggregated 13F filings for Q1 2024.